Kelly Tseng, (Life Sciences) is the recipient of a new sponsored research program with Provectus Biopharmaceuticals, a clinical-stage biotechnology company. The project is to investigate and characterize the effects of Provectus' drug product on vertebrate tissue regeneration and repair.
Comments
Share your thoughts about this story. To comment, you'll need to login into your Facebook account. Your comment will post immediately. Comments that are not in keeping with our comment policies may be removed by editors.